Multiple Myeloma: « 20 » and « 100 » Ratios Cut-off applicable to Sebia FLC assays

Publication
Feb. 29, 2024

The « 20 » and « 100 » Ratios Cut-off can be used in routine with Sebia FLC assays for high-risk smoldering multiple myeloma stratification and for assessing progression to active multiple myeloma or amyloidosis.

Experience and recommendations of a Major Cancer Center to use HYDRASHIFT daratumumab

Publication
Aug. 09, 2021

Immunotherapies for Multiple Myeloma, like the monoclonal antibody daratumumab, can create false positive IgG Kappa bands on Immunofixation gels. This paper describes best practice guidelines for using the Hydrashift assay to remove daratumumab interference from Immunofixation gels.

HYDRASHIFT avoids monoclonal antibody interference on IMMUNOFIXATION

Publication
Jun. 11, 2021

The HYDRASHIFT portfolio include IVD test to mitigate interferences seen in immunofixation result for patient treated with daratumumab.

Effects of hemoglobin C, D, E and S traits on measurements of hemoglobin A1c by twelve methods

Publication
Jun. 11, 2021

Hemoglobin C, D Punjab, E or S trait can interfere with hemoglobin A1c (HbA1c) results depending on the method of analysis used. Therefore, it is important to know the limitations of the method used for HbA1c determination.

The impact of red blood cell lifespan on HbA1c measurement

Publication
Jun. 11, 2021

This article reminds the reader of the importance of detecting the Hb variants when measuring HbA1c for the labs and clinicians to better interpret the results and to ensure optimal management of the diabetic patient.

EurA1c trial

Publication
Jun. 11, 2021

The EurA1c trial, organized yearly, investigates the performance of HbA1c assays across countries and manufacturers.

Precision of CAPILLARYS 2 for the Detection of Hemoglobin Variants Based on Their Migration Positions

Publication
Jun. 11, 2021

In this report, we evaluated the use of the capillary electrophoresis (CE) migration position in the CAPILLARYS 2 CE instrument.

Further evaluation of the world health organization international reference reagent for Haemoglobin A2 measurement

Publication
Jun. 11, 2021

This article assesses the performances of the different manufacturers and technologies (HPLC and CE) for Hb A2 measurement using both International Reference Reagent for HbA2 (WHO IRR 89/666) and analysis of three whole blood specimens over a range of HbA2, distributed to 56 laboratories located in 14 different countries.